Abstract
Background: Papillary thyroid cancer (PTC) is the most common type of thyroid malignancy. Serum thyroglobulin (Tg) levels are used to monitor PTC treatment response and recurrences however, in about 25% of the cases the sensitivity of this method is compromised due to either the presence of neutralizing anti-Tg antibodies (TgAb) or the absence of Tg in less differentiated tumors. Up to 80% of PTC tumors harbor the c.1799T>A hotspot mutation in the BRAF gene (BRAFV600E). Here, we assessed the potential use of plasma cell-free BRAFV600E mutant tumor DNA (ctDNA) levels in determining the minimal residual tumor status of PTC patients.Methods: Patients were classified as either having persistent disease (PD) or no evidence of disease (NED) based on clinicopathological assessments. Tumor BRAFV600E status was determined by both direct sequencing and digital PCR. Plasma total cell-free BRAFV600 wild type DNA (cfDNA) and ctDNA fractions circulating in the plasma of PTC patients were determined by an emulsion based-digital PCR and total ctDNA was quantified by 3D digital PCR. The total ctDNA levels (copies/ml) were then compared to patients' clinicopathological features.Results: About 74% (28/38) of tumors harbored the BRAFV600E mutation. Percent plasma ctDNA fractions for PD patients with BRAFV600E tumors ranged from 0 to 2.07%, whereas absolute plasma ctDNA copies ranged from 0 to 62 copies. The ctDNA levels accurately detected tumor burden of PTC patients whose tumors harbored BRAFV600E; median plasma ctDNA copy numbers were significantly higher (Wilcoxon test, p = 0.03) in patients with metastasis (MET) (20 copies/ml) compared to patients with non-metastatic (non-MET) tumors (1 copy/ml). The plasma ctDNA levels (copies/ml) accurately determined the disease status of PTC patients with sensitivity of 86% and specificity of 90% as compared to 78% sensitivity and 65% specificity determined by serum Tg levels (ng/ml) with areas under the curves (AUC) of 0.88 and 0.71, respectively. Intriguingly, plasma total cfDNA levels were significantly higher in patients with no evidence of residual disease (NED) compared to persistent disease (PD) patients.Conclusions: Our study supports the clinical applicability of plasma ctDNA as biomarker to determine the residual tumor status and tumor burden of PTC patients.
Highlights
The incidence of papillary thyroid cancer (PTC) has dramatically increased in the United States and most other developed countries in the last three decades [1, 2]
The PTC patients were classified as having persistent disease (PD) and no evidence of disease (NED) based on radiological and other clinicopathological assessments combined if necessary; of the 38 PTC patients, 18 patients had PD and 20 had no evidence of residual disease (NED)
Our main findings are summarized in the following points; first, the BEAMing assay was able to accurately detect the disease status of PTC patients with over 86% sensitivity and 90% specificity; second, plasma cell-free BRAFV600E mutant tumor DNA (ctDNA) levels predicted the tumor burden; third, we found that the overall total cellfree BRAFV600 wild type DNA (cfDNA) levels of NED patients were higher than those of PDs
Summary
The incidence of papillary thyroid cancer (PTC) has dramatically increased in the United States and most other developed countries in the last three decades [1, 2]. Since the initial report in 1975, serum Tg level has become the gold standard tumor marker for detecting persistent/recurrent PTCs after initial therapies. In about 25% of the cases, the presence of elevated anti-Tg antibodies (TgAb) interferes with most Tg assays making this technique unreliable for clinical assessment of PTCs [4, 5]. There is a clear need for additional more sensitive and safe molecular assays to efficiently monitor PTC patients. Serum thyroglobulin (Tg) levels are used to monitor PTC treatment response and recurrences in about 25% of the cases the sensitivity of this method is compromised due to either the presence of neutralizing anti-Tg antibodies (TgAb) or the absence of Tg in less differentiated tumors. We assessed the potential use of plasma cell-free BRAFV600E mutant tumor DNA (ctDNA) levels in determining the minimal residual tumor status of PTC patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
